Zenith Capital Corp. (ZHCLF) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $27.2M is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerZenith Capital Corp. (ZHCLF) trades at $0.17. Zenith Capital Corp. is a biotechnology investment company focused on the discovery and development of novel therapeutics. Founded in 2013, the company operates primarily in the healthcare sector. Market cap: $27.2M, Sector: Healthcare.
Price as of Sep 10, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for ZHCLF: ZHCLF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ZHCLF against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
ZHCLF: 1/2 scored disciplines lean bullish. Dominant signal: Ray Dalio bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Zenith Capital Corp. (ZHCLF) Healthcare & Pipeline Overview
Zenith Capital Corp., a biotechnology investment firm founded in 2013, focuses on discovering and developing novel therapeutics. Operating within the high-risk, high-reward biotechnology sector, the company faces significant competition and regulatory hurdles while pursuing innovative healthcare solutions. Its financial performance reflects the challenges inherent in early-stage biotech ventures.
What Is the Investment Thesis for ZHCLF?
Zenith Capital Corp. presents a high-risk, high-reward investment profile characteristic of early-stage biotechnology ventures. With a market capitalization of $27.2M and a negative P/E ratio of -3.39, the company's financial performance reflects its investment phase. A gross margin of 100.0% suggests potential profitability upon successful commercialization of therapeutics, but the negative profit margin of -1406.2% underscores current operational losses. The company's beta of -161.71 indicates extreme volatility relative to the market. Key value drivers include successful clinical trials and regulatory approvals for its portfolio companies. Upcoming catalysts involve advancements in the drug development pipeline and potential partnerships. Potential risks include clinical trial failures, regulatory setbacks, and funding challenges.
Based on FMP financials and quantitative analysis
ZHCLF Key Highlights
Market capitalization of $27.2M, reflecting its small size and early stage of development.
- Negative P/E ratio of -3.39, indicating current losses and limited earnings.
- Gross margin of 100.0%, suggesting potential profitability upon successful commercialization of therapeutics.
- Profit margin of -1406.2%, highlighting significant operational losses.
- Beta of -161.71, indicating extreme volatility relative to the market.
Who Are ZHCLF's Competitors?
ZHCLF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| CLCS Cell Source, Inc. | $0.45 | -33.82% | $30.6M | — |
| RLYB Rallybio Corporation | $16.75 | -1.30% | $88.9M | — |
| ICCC ImmuCell Corporation | $9.91 | +0.05% | $89.7M | — |
| ORMP Oramed Pharmaceuticals Inc. | $4.74 | -0.84% | $194M | — |
| NAGE Niagen Bioscience Inc | $3.04 | -0.49% | $242M | — |
| QTTB Q32 Bio Inc. | $10.77 | -3.37% | $320M | — |
| NWPHF Newron Pharmaceuticals S.p.A. | $20.00 | 0.00% | $416M | — |
| CRMD CorMedix Inc. | $7.93 | -2.40% | $623M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ZHCLF's Key Strengths?
Expertise in biotechnology investments
- Strong network within the industry
- Potential for high returns on successful therapeutics
What Are ZHCLF's Weaknesses?
High risk associated with early-stage ventures
- Dependence on clinical trial outcomes
- Limited revenue generation in the short term
What Could Drive ZHCLF Stock Higher?
Clinical trial results for key therapeutic candidates.
- Strategic partnerships with pharmaceutical companies.
- Advancements in drug development pipeline.
What Are the Key Risks for ZHCLF?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures.
- Regulatory setbacks.
- Competition from established pharmaceutical companies.
- Funding challenges for early-stage ventures.
- Market volatility impacting biotechnology investments.
What Are the Growth Opportunities for ZHCLF?
- Advancement of Drug Pipeline: Zenith Capital's growth hinges on the successful advancement of its drug pipeline through clinical trials. Positive clinical trial results can significantly increase the value of its portfolio companies, attracting further investment and potential partnerships. The timeline for this growth opportunity is dependent on the stage of development of each therapeutic candidate, with potential catalysts occurring within the next 1-3 years as trials progress. The market size for successful therapeutics is substantial, potentially reaching billions of dollars per drug.
- Strategic Partnerships and Acquisitions: Forming strategic partnerships with larger pharmaceutical companies or pursuing acquisitions of promising biotechnology ventures can accelerate Zenith Capital's growth. These partnerships can provide access to additional funding, expertise, and distribution networks. The timeline for this growth opportunity is variable, depending on market conditions and the availability of suitable partners or acquisition targets. The potential market size is significant, as partnerships can unlock access to global markets and expand the company's therapeutic focus.
- Expansion into New Therapeutic Areas: Expanding its investment focus into new therapeutic areas, such as gene therapy or immunotherapy, can diversify Zenith Capital's portfolio and reduce its reliance on specific drug candidates. This expansion can open up new market opportunities and attract investment from specialized funds. The timeline for this growth opportunity is medium-term, requiring careful evaluation of new therapeutic areas and identification of promising investment targets. The market size for emerging therapeutic areas is substantial, with significant growth potential in the coming years.
- Capitalizing on Regulatory Changes: Changes in regulatory policies, such as expedited approval pathways for certain drugs, can create opportunities for Zenith Capital to accelerate the development and commercialization of its therapeutics. Staying informed about regulatory changes and adapting its strategies accordingly can provide a competitive advantage. The timeline for this growth opportunity is dependent on regulatory developments, which can occur unexpectedly. The potential market size is significant, as faster approval times can lead to earlier revenue generation and increased profitability.
- Leveraging Artificial Intelligence: Integrating artificial intelligence (AI) into its drug discovery and development processes can improve the efficiency and effectiveness of Zenith Capital's research efforts. AI can be used to identify promising drug candidates, predict clinical trial outcomes, and optimize drug formulations. The timeline for this growth opportunity is ongoing, as AI technologies continue to evolve and become more accessible. The potential market size is substantial, as AI-driven drug discovery can significantly reduce development costs and accelerate the time to market.
What Are ZHCLF's Competitive Advantages?
- Expertise in identifying and evaluating promising therapeutic candidates.
- Established network of contacts within the biotechnology industry.
- Access to capital for funding early-stage ventures.
What Does ZHCLF Do?
Zenith Capital Corp., established on April 10, 2013, by Donald J. McCaffrey, is a biotechnology investment company headquartered in Calgary, Canada. The company's core mission revolves around the discovery and development of novel therapeutics. Zenith Capital operates within the highly competitive and regulated biotechnology industry, seeking to identify and advance promising therapeutic candidates. As an investment company, Zenith Capital likely focuses on funding and supporting early-stage biotechnology ventures, providing capital and expertise to facilitate the development of innovative treatments. The company's success hinges on its ability to identify and nurture promising therapeutic candidates, navigate the complex regulatory landscape, and secure strategic partnerships. Zenith Capital's operations are concentrated in the biotechnology sector, where it aims to contribute to advancements in healthcare through strategic investments in novel therapeutics. The company's long-term growth prospects are tied to the success of its portfolio companies and the overall health of the biotechnology industry.
What Products and Services Does ZHCLF Offer?
- Invests in biotechnology companies focused on novel therapeutics.
- Provides capital and expertise to early-stage biotechnology ventures.
- Supports the development of innovative treatments for various diseases.
- Identifies and nurtures promising therapeutic candidates.
- Navigates the complex regulatory landscape of the biotechnology industry.
- Seeks strategic partnerships to accelerate drug development and commercialization.
How Does ZHCLF Make Money?
- Invests in early-stage biotechnology companies.
- Provides funding and resources to support drug development.
- Generates returns through successful clinical trials and commercialization of therapeutics.
What Industry Does ZHCLF Operate In?
Zenith Capital Corp. operates within the biotechnology industry, a sector characterized by intense competition, high research and development costs, and stringent regulatory oversight. Key trends include the increasing adoption of artificial intelligence in drug discovery and the growing demand for novel therapies for chronic diseases. Zenith Capital competes with established pharmaceutical companies and other biotechnology firms, including ACMSY (Acacia Research Corporation), CLCS (Caladrius Biosciences, Inc.), GLABF (Global BioLife Inc), HSITF (HygroScience Inc), and NYMXF (Nymox Pharmaceutical Corp).
Who Are ZHCLF's Key Customers?
- Biotechnology companies seeking funding and expertise.
- Investors interested in the biotechnology sector.
- Pharmaceutical companies looking for strategic partnerships.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● Latest filing 223 days ago
- ● No analyst coverage
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 60 |
| 2026-08-26 | 60 |
| 2026-08-29 | 60 |
| 2026-09-01 | 60 |
| 2026-09-04 | 60 |
| 2026-09-07 | 60 |
| 2026-09-10 | 60 |
What changed?
The score has stayed at 60.
Over the same 18 days the stock moved +240.0%.
Zenith Capital Corp. Financial Trajectory
Zenith Capital Corp. (ZHCLF) reported $0 in revenue for Q3 FY2025, based on the latest filing compared to the prior quarter. The company recorded a net loss of $2.7M, with diluted EPS of $-0.02. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, ZHCLF averaged $-0.01 in diluted EPS.
Company Profile
Zenith Capital Corp. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Calgary, CA. The company is led by CEO Donald J. McCaffrey. ZHCLF has traded publicly since 2021.
How Zenith Capital Corp. Is Valued
Zenith Capital Corp. carries a market capitalization of $27.2M, placing it in the micro-cap category.
Financial Health
Zenith Capital Corp.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
ZHCLF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Expertise in biotechnology investments
- Strong network within the industry
- Potential for high returns on successful therapeutics
- Upcoming: Clinical trial results for key therapeutic candidates.
Bear Case
- High risk associated with early-stage ventures
- Dependence on clinical trial outcomes
- Limited revenue generation in the short term
- Potential: Clinical trial failures.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 FY2025 | $0 | -$3M | -$0.02 |
| Q2 FY2025 | $0 | -$2M | -$0.01 |
| Q1 FY2025 | $0 | -$2M | -$0.01 |
| Q4 FY2024 | $500,000 | -$2M | -$0.01 |
Q3 FY2025 · filed 31 Jan 2026 · Financial Modeling Prep
Based on FMP financials and quantitative analysis
ZHCLF Latest News
No recent news available for ZHCLF.
ZHCLF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for ZHCLF.
Price Targets
Wall Street price target analysis for ZHCLF.
ZHCLF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for ZHCLF; grades run from A+ (80-100) to F (below 30).
Leadership: Donald J. McCaffrey
CEO
Donald J. McCaffrey is the founder and CEO of Zenith Capital Corp. His background likely includes experience in finance, biotechnology, or a related field. As the founder, he has been instrumental in shaping the company's vision and strategy. His leadership is critical to navigating the challenges of the biotechnology industry and securing funding for early-stage ventures.
Track Record: As the CEO of Zenith Capital Corp. since its inception in 2013, Donald J. McCaffrey has overseen the company's investments in various biotechnology ventures. His key achievements include establishing the company, securing initial funding, and building a portfolio of promising therapeutic candidates. The company's milestones under his leadership include advancing drug candidates through preclinical and clinical trials. However, specific details about successful exits or commercialized products are not available in the provided data.
ZHCLF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Zenith Capital Corp. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be subject to the same level of regulatory scrutiny as those listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and potential for fraud or manipulation.
- OTC Tier: OTC Other
- Limited financial disclosure
- Low trading volume and liquidity
- Potential for fraud or manipulation
- Higher price volatility
- Lack of regulatory oversight
- Verify the company's registration and legal standing.
- Assess the company's financial health and historical performance.
- Review any available financial statements and disclosures.
- Research the company's management team and their track record.
- Understand the company's business model and competitive landscape.
- Evaluate the potential risks and challenges associated with the investment.
- Consult with a qualified financial advisor.
- Company has been in operation since 2013
- Focus on biotechnology investment
- Led by a named CEO, Donald J. McCaffrey
What Investors Ask About Zenith Capital Corp. (ZHCLF) — Healthcare
Is ZHCLF a good stock?
Stock Expert AI does not rate ZHCLF buy, sell or hold. Zenith Capital Corp. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What do analysts say about ZHCLF stock?
As of 2026-03-16, analyst coverage for ZHCLF is not readily available, likely due to its OTC listing and small market capitalization. Key valuation metrics, such as price targets and earnings estimates, are therefore unavailable.
What are the key factors to evaluate for ZHCLF?
Evaluate ZHCLF on fundamentals, analyst consensus, and risk factors. Market capitalization of $27.2M, reflecting its small size and early stage of development. Not financial advice.
How frequently does ZHCLF data refresh on this page?
ZHCLF's price was last updated on Sep 10, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ZHCLF's recent stock price performance?
Zenith Capital Corp. (ZHCLF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Expertise in biotechnology investments. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ZHCLF overvalued or undervalued right now?
Zenith Capital Corp. (ZHCLF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of ZHCLF?
Yes, most major brokerages offer fractional shares of Zenith Capital Corp. (ZHCLF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track ZHCLF's earnings and financial reports?
Zenith Capital Corp. (ZHCLF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for ZHCLF earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on OTC-listed companies.
- Financial data may not be fully up-to-date.